FrancophonIA/ELRC3.0 huggingface dataset:
English: If you take more Zontivity than you are supposed to, talk to a doctor or go to hospital straight away.
Croatian: Ako uzmete više lijeka Zontivity nego što ste trebali, odmah se obratite svom liječniku ili otiđite u bolnicu.
English: Zontivity contains lactose.
Croatian: Zontivity sadrži laktozu.
English: For patients being started on Zontivity due to symptomatic PAD, therapy may be initiated at any time.
Croatian: Kod bolesnika u kojih se Zontivity uvodi zbog simptomatskog PAD-a, terapija može započeti u bilo koje vrijeme.
English: Evaluation of Zontivity on QTc interval
Croatian: Ocjena učinka lijeka Zontivity na QTc interval
English: Vorapaxar should not be used with prasugrel or ticagrelor (see section 4.2).
Croatian: Vorapaksar se ne smije primjenjivati s prasugrelom ni tikagrelorom (vidjeti dio 4.2).
English: Transfusion of human platelet rich plasma normalised bleeding times with partial recovery of ex vivo platelet aggregation induced with arachidonic acid, but not induced with ADP or TRAP.
Croatian: Transfuzija humane plazme bogate trombocitima normalizirala je vremena krvarenja uz djelomičan oporavak ex vivo agregacije trombocita inducirane arahidonskom kiselinom, ali ne i one inducirane ADP-om ili TRAP-om.
English: What Zontivity is and what it is used for What you need to know before you take Zontivity
Croatian: Što se nalazi u ovoj uputi Što je Zontivity i za što se koristi Što morate znati prije nego počnete uzimati Zontivity Kako uzimati Zontivity
English: Zontivity should be used with caution in patients with a body weight <60 kg.
Croatian: Zontivity treba primjenjivati uz oprez u bolesnika tjelesne težine <60 kg.
English: • plan to have surgery including dental surgery
Croatian: • planirate ići na kirurški zahvat, uključujući i stomatološki,
English: CYP2C8 substrates
Croatian: Supstrati za CYP2C8
English: • low red blood cell count (anaemia)
Croatian: • smanjen broj crvenih krvnih stanica (anemija),
English: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
Croatian: Bolesnici s rijetkim nasljednim poremećajima nepodnošenja galaktoze, nedostatka Lapp laktaze ili malapsorpcijom glukoze i galaktoze ne smiju uzimati ovaj lijek.
English: Excipient(s) with known effect: Each film-coated tablet contains 66.12 mg of lactose (as monohydrate).
Croatian: Pomoćna(e) tvar(i) s poznatim učinkom Jedna filmom obložena tableta sadrži 66,12 mg laktoze (u obliku hidrata).
English: EU/1/14/976/001 EU/1/14/976/002 EU/1/14/976/003 EU/1/14/976/004 EU/1/14/976/005 EU/1/14/976/006
Croatian: EU/1/14/976/001 EU/1/14/976/002 EU/1/14/976/003 EU/1/14/976/004
English: Patients should be advised to inform physicians and dentists that they are taking Zontivity before any surgery is scheduled and before any new medicinal product is taken.
Croatian: Bolesnike treba upozoriti da obavijeste liječnike i stomatologe o uzimanju lijeka Zontivity prije nego što dogovore bilo koji kirurški zahvat, odnosno prije nego što uzmu bilo koji novi lijek.
English: • boceprevir, telaprevir (used to treat hepatitis C virus infections)
Croatian: • boceprevir, telaprevir (koriste se za liječenje infekcija virusom hepatitisa C),
English: • Do not stop taking Zontivity without first talking to the doctor who prescribed it for you.
Croatian: • Nemojte prestati uzimati Zontivity ako prethodno o tome niste razgovarali s liječnikom koji
English: • Patients with a history of stroke or transient ischaemic attack (TIA) (see section 5.1).
Croatian: • Bolesnici s moždanim udarom ili tranzitornom ishemijskom atakom (TIA) u anamnezi (vidjeti dio 5.1).
English: • if you have ever had a stroke or ‘mini stroke' (also called a ‘transient ischemic attack' or TIA)
Croatian: • ako ste ikada imali moždani udar ili mali moždani udar (koji se naziva i tranzitorna ishemijska ataka ili TIA),
English: Your doctor will also give you instructions about acetylsalicylic acid or clopidogrel (other anti-platelet agents) that you may need to take with Zontivity.
Croatian: Liječnik će Vam također dati upute o acetilsalicilatnoj kiselini ili klopidogrelu (drugi antitrombocitni lijekovi) koje ćete možda trebati uzimati s lijekom Zontivity.
English: No dose adjustment for vorapaxar is required in patients taking weak to moderate inhibitors of CYP3A.
Croatian: Nije potrebno prilagođavati dozu vorapaksara u bolesnika koji uzimaju slabe do umjerene inhibitore CYP3A.
English: In humans, vorapaxar has been administered in single doses up to 120 mg and daily doses of 5 mg for up to 4 weeks without observation of dose-associated adverse events or identification of a specific risk.
Croatian: U ljudi se vorapaksar primjenjivao u jednokratnim dozama do 120 mg na dan i dnevnim dozama od 5 mg tijekom najviše 4 tjedna, a da pritom nisu primijećeni štetni događaji povezani s dozom niti je identificiran neki specifičan rizik.
English: If your doctor prescribes you prasugrel or ticagrelor, you should stop Zontivity and talk to your doctor.
Croatian: Ako Vam je liječnik propisao prasugrel ili tikagrelor, prestanite uzimati Zontivity i obavijestite svog liječnika.
English: Bleeding should be suspected in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or other surgical procedures, even if the patient does not have any signs of bleeding.
Croatian: Na krvarenje treba posumnjati u svakog bolesnika koji ima hipotenziju, a nedavno je bio podvrgnut koronarnoj angiografiji, perkutanoj koronarnoj intervenciji (PKI), ugradnji premosnice koronarnih arterija (engl. coronary artery bypass graft, CABG) ili nekom drugom kirurškom zahvatu, čak i ako bolesnik ne pokazuje nikakve znakove krvarenja.
English: There are limited data on the efficacy and safety of Zontivity beyond 24 months.
Croatian: Podaci o djelotvornosti i sigurnosti primjene lijeka Zontivity za period dulji od 24 mjeseca su ograničeni.
English: Do not take Zontivity if you are currently being treated with prasugrel or ticagrelor (other anti-platelet agents).
Croatian: Nemojte uzimati Zontivity ako se trenutno liječite prasugrelom ili tikagrelorom (drugi antitrombocitni lijekovi).
English: Vorapaxar had no effect on the QTc interval at single doses up to 120 mg.
Croatian: Vorapaksar nije imao nikakav učinak na QTc interval kada se primjenjivao u jednokratnim dozama do 120 mg.
English: This background therapy was to be continued during the trial at the treating physician's discretion, per standard of care.
Croatian: Ta se osnovna terapija trebala nastaviti i tijekom ispitivanja prema odluci liječnika, sukladno standardnom liječenju.
English: Effects of other medicinal products on vorapaxar
Croatian: Učinci drugih lijekova na vorapaksar
English: Co-administration with vorapaxar did not alter the single-dose pharmacokinetics of rosiglitazone (8 mg), a CYP2C8 substrate not marketed in the EU.
Croatian: Istodobna primjena s vorapaksarom nije izmijenila farmakokinetiku jednokratne doze roziglitazona (8 mg), supstrata za CYP2C8 koji se ne nalazi na tržištu u EU.
English: • if you have severe liver disease
Croatian: • ako imate tešku bolest jetre.
English: As vorapaxar is highly protein-bound, haemodialysis is unlikely to be effective in the treatment of an overdose.
Croatian: Budući da se vorapaksar u velikoj mjeri veže za proteine, nije vjerojatno da će hemodijaliza biti djelotvorna u liječenju predoziranja.
English: Zontivity should be initiated at least 2 weeks after a MI and preferably within the first 12 months from the acute event (see section 5.1).
Croatian: Liječenje lijekom Zontivity treba započeti najmanje 2 tjedna nakon IM-a i, po mogućnosti, unutar prvih 12 mjeseci nakon akutnog događaja (vidjeti dio 5.1).
English: Platelet inhibition with vorapaxar is gradual and reversible.
Croatian: Inhibicija trombocita pri liječenju vorapaksarom je postupna i reverzibilna.
English: General risk of bleeding
Croatian: Općenit rizik od krvarenja
English: Vorapaxar should not be initiated in patients taking prasugrel or ticagrelor and in case of need for additional therapy with these agents, vorapaxar should be stopped.
Croatian: Liječenje vorapaksarom ne smije se započeti u bolesnika koji uzimaju prasugrel ili tikagrelor, a u slučaju potrebe za dodatnom terapijom tim lijekovima, liječenje vorapaksarom mora se prekinuti.
English: The combination of vorapaxar with warfarin or other oral anticoagulants may increase the risk of bleeding and should be avoided.
Croatian: Kombinacija vorapaksara s varfarinom ili drugim peroralnim antikoagulansima može povećati rizik od krvarenja i stoga je treba izbjegavati.
English: Consistent with its selective molecular target (PAR-1), vorapaxar has no effect on ADP-induced platelet aggregation in healthy subjects and patient populations.
Croatian: Budući da djeluje selektivno na ciljnu molekulu (PAR-1), vorapaksar ne utječe na ADP-om induciranu agregaciju trombocita u zdravih ispitanika ni u populacijama bolesnika.
English: Within that period the effect was similar regardless of the time from qualifying MI to the start of therapy with Zontivity.
Croatian: U tom je razdoblju učinak bio sličan neovisno o vremenu od IM-a koji je bolesnika kvalificirao za ispitivanje do početka terapije lijekom Zontivity.
English: In general, use of anti-platelet medicines, older age, or a low body weight increase the risk of bleeding.
Croatian: Primjena antitrombocitnih lijekova, starija dob ili niska tjelesna težina općenito povećavaju rizik od krvarenja.
English: Vorapaxar was not mutagenic or genotoxic in a battery of in vitro and in vivo studies.
Croatian: Vorapaksar nije bio ni mutagen ni genotoksičan u nizu ispitivanja in vitro i in vivo.
English: Vorapaxar is a weak inhibitor of the intestinal P-glycoprotein (P-gp) transporter.
Croatian: Vorapaksar je slab inhibitor prijenosnika P-glikoproteina (P-gp) u crijevima.
English: D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
Croatian: UVJETI ILI OGRANIČENJA VEZANI UZ SIGURNU I UČINKOVITU PRIMJENU LIJEKA
English: Zontivity has no or negligible influence on the ability to drive and use machines.
Croatian: Zontivity ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Anticoagulants
Croatian: Antikoagulansi
English: Schering-Plough Labo N.V. Industriepark 30
Croatian: Schering-Plough Labo N.V.
English: The systemic exposure of M20 is ~20% of the exposure to vorapaxar.
Croatian: Sistemska izloženost metabolitu M20 iznosi ~20% izloženosti vorapaksaru.
English: Patients were randomized to receive daily treatment with 2.5 mg vorapaxar sulfate (n=13,225) or placebo (n=13,224) in addition to other standard therapy.
Croatian: Bolesnici su bili randomizirani za primanje dnevne terapije vorapaksarsulfatom u dozi od 2,5 mg (n=13 225) ili placebom (n=13 224), kao dodataka drugoj standardnoj terapiji.
English: Talk to your doctor, pharmacist, or nurse before taking Zontivity if you:
Croatian: Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Zontivity ako:
English: If you stop taking Zontivity
Croatian: Ako prestanete uzimati Zontivity
English: Call your doctor straight away if you have any of these symptoms of a stroke, which is uncommon:
Croatian: Odmah se javite svom liječniku ako primijetite bilo koji od sljedećih simptoma moždanog udara, koji se javlja manje često:
English: Medicinal products that increase gastric pH
Croatian: Lijekovi koji povisuju želučani pH
English: There are no data on fertility in humans administered Zontivity.
Croatian: Nema podataka o utjecaju na plodnost u ljudi kojima je primijenjen Zontivity.
English: Vorapaxar and the major circulating active metabolite, M20, are extensively bound (≥99%) to human plasma proteins.
Croatian: Vorapaksar i M20, njegov glavni aktivni metabolit u cirkulaciji, u velikoj se mjeri (≥99%) vezuju za proteine u plazmi ljudi.
English: Vorapaxar is eliminated primarily in the form of metabolites, with no vorapaxar detected in urine.
Croatian: Vorapaksar se prvenstveno eliminira u obliku metabolita i nije pronađen u mokraći.
English: TRA 2°P - TIMI 50 was a multicenter, randomized, double-blind, placebo-controlled study conducted in patients who had evidence or a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems.
Croatian: Ispitivanje TRA 2°P - TIMI 50 bilo je multicentrično, randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje provedeno u bolesnika koji su pokazivali znakove ili su u anamnezi imali aterosklerozu koja je zahvaćala srčani, moždani ili periferni vaskularni sustav.
English: • nefazodone (used to treat depression)
Croatian: • nefazodon (koristi se za liječenje depresije),
English: The primary route of elimination is through the faeces, with approximately 91.5% of radiolabeled dose predicted to be recovered in the faeces compared to 8.5% in the urine.
Croatian: Primarni put eliminacije je fecesom, pa se predviđa da će približno 91,5% radioaktivno označene doze biti pronađeno u fecesu, a svega 8,5% u mokraći.
English: No relevant effects were observed in animals (see section 5.3).
Croatian: Nisu primijećeni relevantni učinci u životinja (vidjeti dio 5.3).
English: Zontivity and lactose
Croatian: Zontivity i laktoza
English: • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see section 4.4).
Croatian: • Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1 (vidjeti dio 4.4).
English: The tablet may be taken with or without food.
Croatian: Tablete se mogu uzimati s hranom ili bez nje.
English: There is no known treatment to reverse the antiplatelet effect of Zontivity.
Croatian: Nema poznate terapije kojom bi se poništio antitrombocitni učinak lijeka Zontivity.
English: If you forget to take Zontivity
Croatian: Ako ste zaboravili uzeti Zontivity
English: Vorapaxar is a selective and reversible inhibitor of the PAR-1 receptors on platelets that are activated by thrombin.
Croatian: Vorapaksar je selektivan i reverzibilan inhibitor PAR-1 receptora na trombocitima koje aktivira trombin.
English: • dying from a heart attack
Croatian: • smrti zbog srčanog udara,
English: Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excluding heparin, ATC code: B01AC26.
Croatian: Farmakoterapijska skupina: Antitrombotici, inhibitori agregacije trombocita (osim heparina), ATK oznaka: B01AC26.
English: EU/1/14/976/001 7 film-coated tablets EU/1/14/976/002 10 x 1 film-coated tablets (unit-dose) EU/1/14/976/003 28 film-coated tablets EU/1/14/976/004 30 film-coated tablets EU/1/14/976/005 50 x 1 film-coated tablets (unit-dose) EU/1/14/976/006 100 film-coated tablets
Croatian: EU/1/14/976/001 7 filmom obloženih tableta EU/1/14/976/002 10 x 1 filmom obložena tableta (djeljivo na jedinične doze) EU/1/14/976/003 28 filmom obloženih tableta EU/1/14/976/004 30 filmom obloženih tableta EU/1/14/976/005 50 x 1 filmom obložena tableta (djeljivo na jedinične doze) EU/1/14/976/006 100 filmom obloženih tableta
English: Includes all CV Death, MI, Stroke and GUSTO severe events up to each timepoint as indicated in the table.
Croatian: Uključuje sve događaje smrti zbog KV uzroka, IM-a, moždanog udara i teške događaje prema GUSTO kriterijima do pojedine vremenske točke navedene u tablici.
English: Vorapaxar is eliminated by metabolism, with CYP3A4 and CYP2J2 responsible for formation of M20, its major active circulating metabolite, and M19, the predominant metabolite identified in excreta.
Croatian: Vorapaksar se eliminira metabolizmom, u kojem su CYP3A4 i CYP2J2 odgovorni za stvaranje metabolita M20, njegova glavnog aktivnog metabolita u cirkulaciji, te metabolita M19, koji prevladava u tjelesnim izlučevinama.
English: In these subgroups, Zontivity should only be prescribed after careful assessment of individual potential risks and benefits and the need for co-medication that may further increase the risk of bleeding.
Croatian: U tim se podskupinama Zontivity smije propisati samo nakon pažljive procjene mogućih rizika i koristi u pojedinog bolesnika te potrebe za istodobnom primjenom drugih lijekova koji bi dodatno mogli povećati rizik od krvarenja.
English: Therefore, vorapaxar should not be used with prasugrel or ticagrelor.
Croatian: Stoga se vorapaksar ne smije primjenjivati s prasugrelom ni tikagrelorom.
English: What Zontivity contains
Croatian: Što Zontivity sadrži
English: Strong CYP3A inhibitors
Croatian: Potentni inhibitori CYP3A
English: You and your doctor will decide if you will take Zontivity.
Croatian: Vi i Vaš liječnik donijet ćete odluku o tome hoćete li uzimati Zontivity.
English: Ingestion of vorapaxar with a high-fat meal resulted in no meaningful change in AUC with a small (21%) decrease in Cmax and delayed tmax (45 minutes).
Croatian: Uzimanje vorapaksara uz obrok s visokim udjelom masnoća nije dovelo do značajne promjene AUC-a, uz malo (21%) snižavanje Cmax i produljeni tmax (45 minuta).
English: Acetylsalicylic acid, vorapaxar, and clopidogrel in combination produced significant prolongation of bleeding time.
Croatian: Kombinacija acetilsalicilatne kiseline, vorapaksara i klopidogrela značajno je produljila vrijeme krvarenja.
English: Zontivity is contraindicated in patients with severe hepatic impairment (Child Pugh, 10 to 15 points) (see sections 4.3 and 4.4).
Croatian: Zontivity je kontraindiciran u bolesnika s teškim oštećenjem funkcije jetre (Child Pugh: 10-15 bodova) (vidjeti dijelove 4.3 i 4.4).
English: Based on population pharmacokinetic analysis using data from healthy subjects and patients with atherosclerotic disease, vorapaxar mean AUC is estimated to be higher in patients with mild (17%) and moderate (34%) renal impairment compared to those with normal renal function; these differences are not considered to be clinically relevant.
Croatian: Na temelju populacijske farmakokinetičke analize podataka prikupljenih u zdravih ispitanika i bolesnika s aterosklerotskom bolešću, procjenjuje se da je srednja vrijednost AUC-a vorapaksara veća u bolesnika s blagim (17%) i umjerenim (34%) oštećenjem funkcije bubrega nego u ispitanika s normalnom funkcijom bubrega; te se razlike ne smatraju klinički značajnima.
English: Phase 3 data suggest that co-administration of a weak or moderate CYP3A inhibitor with vorapaxar does not increase bleeding risk or alter the efficacy of vorapaxar.
Croatian: Podaci iz ispitivanja faze 3 upućuju na to da istodobna primjena slabog ili umjerenog inhibitora CYP3A s vorapaksarom ne povećava rizik od krvarenja i ne mijenja djelotvornost vorapaksara.
English: • having another heart attack or stroke
Croatian: • ponovnog srčanog udara ili moždanog udara,
English: HR 95% CI p-value (Z) vs (P) 0.83 (0.76, 0.90) <.001
Croatian: HR 95% CI p-vrijednost Zontivity naspram placeba 0,83 (0,76; 0,90) <0,001
English: Zontivity prevents platelets from sticking together.
Croatian: Zontivity sprječava da se krvne pločice zalijepe jedna za drugu.
English: Concomitant use of Zontivity with strong (potent) inducers of CYP3A (e.g., rifampin, carbamazepine and phenytoin) should be avoided.
Croatian: Treba izbjegavati istodobnu primjenu lijeka Zontivity s potentnim induktorima CYP3A (npr. rifampinom, karbamazepinom i fenitoinom).
English: Elderly No dose adjustment is necessary in the elderly (see sections 4.4 and 5.2).
Croatian: Nije potrebno prilagođavati dozu u starijih osoba (vidjeti dijelove 4.4 i 5.2).
English: Vorapaxar exposure (AUC and Cmax) in patients of African descent is estimated to be 17-19% lower compared to that of Caucasians.
Croatian: Procjenjuje se da je izloženost vorapaksaru (AUC i Cmax) u bolesnika afričkog podrijetla 17-19% niža nego u bijelaca.
English: Vorapaxar did not increase bleeding time in non-human primates when administered alone at 1 mg/kg.
Croatian: Vorapaksar nije produljio vrijeme krvarenja u nečovjekolikih primata kada se primjenjivao samostalno u dozi od 1 mg/kg.
English: • unexpected bleeding or bleeding that lasts a long time
Croatian: • neočekivano ili dugotrajno krvarenje,
English: Due to the unknown potential for adverse reactions in breast-feeding infants from Zontivity, discontinue breast-feeding or discontinue Zontivity; taking into account the importance of the medicinal product to the mother.
Croatian: Budući da nije poznato može li Zontivity uzrokovati nuspojave u dojenčadi, potrebno je prekinuti ili dojenje ili primjenu lijeka Zontivity, uzimajući u obzir važnost lijeka za majku.
English: Co-administration of an aluminium hydroxide/magnesium carbonate antacid or proton pump inhibitor (pantoprazole) did not affect vorapaxar AUC with only small decreases in Cmax.
Croatian: Istodobna primjena antacida koji sadrži aluminijev hidroksid/magnezijev karbonat ili inhibitora protonske pumpe (pantoprazola) nije utjecala na AUC vorapaksara, uz tek neznatno snižavanje Cmax.
English: CV Death
Croatian: Smrt zbog KV uzroka
English: Vorapaxar does not inhibit platelet aggregation induced by other agonists such as adenosine diphosphate (ADP), collagen or a thromboxane mimetic.
Croatian: Vorapaksar ne inhibira agregaciju trombocita induciranu drugim agonistima kao što su adenozin difosfat (ADP), kolagen ili tromboksanski mimetici.
English: Bleeding was the most common adverse reaction leading to study drug discontinuation for both treatments (3.0% for Zontivity and 1.8% for placebo).
Croatian: Kod oba je liječenja krvarenje bila najčešća nuspojava koja je dovodila do prekida primjene ispitivanoga lijeka (3,0% uz Zontivity te 1,8% uz placebo).
English: Patients with events
Croatian: Bolesnici s događajima
English: If you are not sure, talk to your doctor or pharmacist before taking Zontivity.
Croatian: Ako niste sigurni, obratite se svom liječniku ili ljekarniku prije nego uzmete Zontivity.
English: When Zontivity was co-administered with warfarin, there were no alterations in the pharmacokinetics or pharmacodynamics of warfarin.
Croatian: Kada se Zontivity primjenjivao istodobno s varfarinom, nije bilo promjena u farmakokinetici ili farmakodinamici varfarina.
English: Patients with events*
Croatian: Bolesnici s događajima*
English: No dose adjustment is necessary (see section 4.4).
Croatian: Nije potrebno prilagođavati dozu (vidjeti dio 4.4).
English: Blood and lymphatic system disorders
Croatian: Poremećaji krvi i limfnog sustava anemija
English: Zontivity increases the risk of bleeding in proportion to the patient's underlying bleeding risk.
Croatian: Zontivity povećava rizik od krvarenja proporcionalno bolesnikovu već postojećem riziku od krvarenja.
English: In repeat dose oral toxicity studies in rodents and monkeys, the principal treatment-related findings were urinary bladder and ureter hyperplasia in mice, hepatic vascular thrombi, lymphoid necrosis and retinal vacuolation in rats and phospholipidosis in all species.
Croatian: U ispitivanjima toksičnosti ponovljenih doza u glodavaca i majmuna, osnovni nalazi povezani s terapijom bili su hiperplazija mokraćnog mjehura i uretera u miševa, trombi u jetrenim krvnim žilama, limfoidna nekroza i retinalna vakuolizacija u štakora te fosfolipidoza u svih vrsta.
English: • vomiting blood or your vomit looks like ‘coffee grounds'
Croatian: • povraćanje krvi ili povraćanje sadržaja koji nalikuje talogu kave,
English: Zontivity has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization (UCR).
Croatian: Pokazalo se da Zontivity smanjuje stopu mjere kombiniranog ishoda - smrti zbog kardiovaskularnog uzroka te nastupa IM-a, moždanog udara i hitne koronarne revaskularizacije (engl. urgent coronary revascularization, UCR).
English: Bleeding time was prolonged slightly with administration of acetylsalicylic acid alone or in combination with vorapaxar.
Croatian: Vrijeme krvarenja bilo je blago produljeno nakon primjene acetilsalicilatne kiseline same ili u kombinaciji s vorapaksarom.